Read by QxMD icon Read

Boron neutron capture therapy

Silva Bortolussi, Ian Postuma, Nicoletta Protti, Lucas Provenzano, Cinzia Ferrari, Laura Cansolino, Paolo Dionigi, Olimpio Galasso, Giorgio Gasparini, Saverio Altieri, Shin-Ichi Miyatake, Sara J González
BACKGROUND: Osteosarcoma is the most frequent primary malignant bone tumour, and its incidence is higher in children and adolescents, for whom it represents more than 10% of solid cancers. Despite the introduction of adjuvant and neo-adjuvant chemotherapy that markedly increased the success rate in the treatment, aggressive surgery is still needed and a considerable percentage of patients do not survive due to recurrences or early metastases. Boron Neutron Capture Therapy (BNCT), an experimental radiotherapy, was investigated as a treatment that could allow a less aggressive surgery by killing infiltrated tumour cells in the surrounding healthy tissues...
August 15, 2017: Radiation Oncology
Issei Takeuchi, Kensuke Nomura, Kimiko Makino
Poly(DL-lactide-co-glycolide) (PLGA) has been widely used and studied because of its biocompatibility and biodegradability. Recently, the usefulness of nanoparticles using poly(L-lactide-co-glycolide) (PLLGA) having a higher glass transition temperature than PLGA was suggested. In this study, we investigated the availability of boron compound-loaded PLGA and PLLGA nanoparticles for boron neutron capture therapy (BNCT) by conducting biodistribution study using tumor-bearing mice. o-Carborane, a hydrophobic boron compound, was used as a boron carrier, and o-carborane-albumin conjugate was used as a control...
August 4, 2017: Colloids and Surfaces. B, Biointerfaces
Verónica A Trivillin, Emiliano C C Pozzi, Lucas L Colombo, Silvia I Thorp, Marcela A Garabalino, Andrea Monti Hughes, Sara J González, Rubén O Farías, Paula Curotto, Gustavo A Santa Cruz, Daniel G Carando, Amanda E Schwint
The aim of the present study was to evaluate, for the first time, the abscopal effect of boron neutron capture therapy (BNCT). Twenty-six BDIX rats were inoculated subcutaneously with 1 × 10(6) DHD/K12/TRb syngeneic colon cancer cells in the right hind flank. Three weeks post-inoculation, the right leg of 12 rats bearing the tumor nodule was treated with BPA-BNCT (BPA-Boronophenylalanine) at the RA-3 nuclear reactor located in Buenos Aires, Argentina, at an absorbed dose of 7.5 Gy to skin as the dose-limiting tissue...
August 8, 2017: Radiation and Environmental Biophysics
Leyla Moghaddasi, Eva Bezak
Glioblastomas (GBM) are notorious for their high fatality rate. Boron Neutron Capture Therapy (BNCT) being a biochemically targeted type of radiotherapy is a potent modality for GBM. In the current work, a BNCT treatment modelling framework for GBM was developed. Optimal Clinical Target Volume (CTV) margins for GBM-BNCT and the BNCT efficacy have been investigated. The model integrated a cell-based dosimetry model, an in-house-developed epithermal neutron beam model and previously-developed Microscopic Extension Probability (MEP) model...
August 1, 2017: Scientific Reports
Chun-Nan Yeh, Chi-Wei Chang, Yi-Hsiu Chung, Shi-Wei Tien, Yong-Ren Chen, Tsung-Wen Chen, Ying-Cheng Huang, Hsin-Ell Wang, You-Cheng Chou, Ming-Huang Chen, Kun-Chun Chiang, Wen-Sheng Huang, Chung-Shan Yu
Boron neutron capture therapy (BNCT) is a binary therapy that employs neutron irradiation on the boron agents to release high-energy helium and alpha particles to kill cancer cells. An optimal response to BNCT depends critically on the time point of maximal (10)B accumulation and highest tumor to normal ratio (T/N) for performing the neutron irradiation. The aggressive cholangiocarcinoma (CCA) representing a liver cancer that overexpresses COX-2 enzyme is aimed to be targeted by COX-2 selective boron carrier, fenbufen boronopinacol (FBPin)...
July 17, 2017: European Journal of Pharmaceutical Sciences
Charles A Maitz, Aslam A Khan, Peter J Kueffer, John D Brockman, Jonathan Dixson, Satish S Jalisatgi, David W Nigg, Thomas A Everett, M Frederick Hawthorne
Boron neutron capture therapy (BNCT) was performed at the University of Missouri Research Reactor in mice bearing CT26 colon carcinoma flank tumors and the results were compared with previously performed studies with mice bearing EMT6 breast cancer flank tumors. Mice were implanted with CT26 tumors subcutaneously in the caudal flank and were given two separate tail vein injections of unilamellar liposomes composed of cholesterol, 1,2-distearoyl-sn-glycer-3-phosphocholine, and K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the lipid bilayer and encapsulated Na3[1-(2`-B10H9)-2-NH3B10H8] within the liposomal core...
August 2017: Translational Oncology
Kenichi Tanaka, Yoshinori Sakurai, Shin-Ichiro Hayashi, Tsuyoshi Kajimoto, Ryohei Uchida, Hiroki Tanaka, Takushi Takata, Gerard Bengua, Satoru Endo
This study investigated the optimum composition of the MAGAT polymer gel which is to be used in the quality assurance measurement of the thermal neutron, fast neutron and gamma ray components in the irradiation field used for boron neutron capture therapy at the Kyoto University Reactor. Simulations using the PHITS code showed that when combined with the gel, (6)Li concentrations of 0, 10 and 100ppm were found to be potentially usable.
June 15, 2017: Applied Radiation and Isotopes
Jia-Cheng Lee, Keh-Shih Chuang, Yi-Wei Chen, Fang-Yuh Hsu, Fong-In Chou, Sang-Hue Yen, Yuan-Hung Wu
Diffuse intrinsic pontine glioma is a very frustrating disease. Since the tumor infiltrates the brain stem, surgical removal is often impossible. For conventional radiotherapy, the dose constraint of the brain stem impedes attempts at further dose escalation. Boron neutron capture therapy (BNCT), a targeted radiotherapy, carries the potential to selectively irradiate tumors with an adequate dose while sparing adjacent normal tissue. In this study, 12 consecutive patients treated with conventional radiotherapy in our institute were reviewed to evaluate the feasibility of BNCT...
2017: PloS One
Satoru Endo, Hitoshi Sato, Takuto Shimazaki, Erika Nakajima, Kei Kotani, Mitsuru Suda, Tsuyoshi Hamano, Tsuyoshi Kajimoto, Kenichi Tanaka, Masaharu Hoshi
An LBO (Li2B4O7) walled ionization chamber was designed to monitor the epithermal neutron fluence in boron neutron capture therapy clinical irradiation. The thermal and epithermal neutron sensitivities of the device were evaluated using accelerator neutrons from the (9)Be(d, n) reaction at a deuteron energy of 4 MeV (4 MeV d-Be neutrons). The response of the chamber in terms of the electric charge induced in the LBO chamber was compared with the thermal and epithermal neutron fluences measured using the gold-foil activation method...
August 2017: Radiation and Environmental Biophysics
Naresh Kuthala, Raviraj Vankayala, Yi-Nan Li, Chi-Shiun Chiang, Kuo Chu Hwang
Glioblastoma multiforme (GBM) is a very common type of "incurable" malignant brain tumor. Although many treatment options are currently available, most of them eventually fail due to its recurrence. Boron neutron capture therapy (BNCT) emerges as an alternative noninvasive therapeutic treatment modality. The major challenge in treating GBMs using BNCT is to achieve selective imaging, targeting, and sufficient accumulation of boron-containing drug at the tumor site so that effective destruction of tumor cells can be achieved without harming the normal brain cells...
June 16, 2017: Advanced Materials
H Tanaka, Y Sakurai, T Takata, T Watanabe, S Kawabata, M Suzuki, S-I Masunaga, K Taki, K Akabori, K Watanabe, K Ono
The real-time detection of epithermal neutrons forms an important aspect of boron neutron capture therapy. In this context, we developed an epithermal neutron detector based on the combination of a small Eu:LiCaAlF6 scintillator and a quartz fiber in order to fulfill the irradiation-field requirements for boron neutron capture therapy. The irradiation test is performed with the use of a reactor-based neutron source. The thermal and epithermal neutron sensitivities of our epithermal neutron detector are estimated to be 9...
May 2017: Review of Scientific Instruments
Natsuko Kondo, Rolf F Barth, Shin-Ichi Miyatake, Shinji Kawabata, Minoru Suzuki, Koji Ono, Norman L Lehman
We have used boron neutron capture therapy (BNCT) to treat patients in Japan with newly diagnosed or recurrent high-grade gliomas and have observed a significant increase in median survival time following BNCT. Although cerebrospinal fluid dissemination (CSFD) is not usually seen with the current standard therapy of patients with glioblastoma (GBM), here we report that subarachnoid or intraventricular CSFD was the most frequent cause of death for a cohort of our patients with high-grade gliomas who had been treated with BNCT...
May 22, 2017: Journal of Neuro-oncology
Akihiko Masuda, Tetsuro Matsumoto, Kenta Takada, Takahiro Onishi, Kohei Kotaki, Hidenori Sugimoto, Hiroaki Kumada, Hideki Harano, Takeji Sakae
The neutron spectral fluence of an accelerator-based neutron source facility for boron neutron capture therapy (BNCT) based on a proton linac and a beryllium target was evaluated by the unfolding method using a Bonner sphere spectrometer (BSS). A (3)He-proportional-counter-based BSS was used with weak beam during the development of the facility. The measured epithermal neutron spectra were consistent with calculations. The epithermal neutron intensity at the beam port was estimated and the results gave a numerical target for the enhancement of the proton beam intensity and will be used as reference data for measurements performed after the completion of the facility...
May 10, 2017: Applied Radiation and Isotopes
Xingcai Guan, Masanobu Manabe, Shingo Tamaki, Fuminobu Sato, Isao Murata, Tieshan Wang
The neutron flux monitors from 10keV to 1MeV designed for boron neutron capture therapy (BNCT) were experimentally tested with prototype monitors in an appropriate neutron field produced at the intense deuterium-tritium neutron source facility OKTAVIAN of Osaka University, Japan. The experimental test results and related analysis indicated that the performance of the monitors was good and the neutron fluxes from 10keV to 1MeV of practical BNCT neutron sources can be measured within 10% by the monitors.
April 12, 2017: Applied Radiation and Isotopes
Joo-Young Jung, Do-Kun Yoon, Brendan Barraclough, Heui Chang Lee, Tae Suk Suh, Bo Lu
The aim of this study is to compare between proton boron fusion therapy (PBFT) and boron neutron capture therapy (BNCT) and to analyze dose escalation using a Monte Carlo simulation. We simulated a proton beam passing through the water with a boron uptake region (BUR) in MCNPX. To estimate the interaction between neutrons/protons and borons by the alpha particle, the simulation yielded with a variation of the center of the BUR location and proton energies. The variation and influence about the alpha particle were observed from the percent depth dose (PDD) and cross-plane dose profile of both the neutron and proton beams...
June 13, 2017: Oncotarget
Tiago H Ferreira, Marcelo C Miranda, Zildete Rocha, Alexandre S Leal, Dawidson A Gomes, Edesia M B Sousa
Currently, nanostructured compounds have been standing out for their optical, mechanical, and chemical features and for the possibilities of manipulation and regulation of complex biological processes. One of these compounds is boron nitride nanotubes (BNNTs), which are a nanostructured material analog to carbon nanotubes, but formed of nitrogen and boron atoms. BNNTs present high thermal stability along with high chemical inertia. Among biological applications, its biocompatibility, cellular uptake, and functionalization potential can be highlighted, in addition to its eased utilization due to its nanometric size and tumor cell internalization...
April 12, 2017: Nanomaterials
Satoshi Nakamura, Akihisa Wakita, Masashi Ito, Hiroyuki Okamoto, Shie Nishioka, Kotaro Iijima, Kazuma Kobayashi, Teiji Nishio, Hiroshi Igaki, Jun Itami
The multi-foil method is commonly used to determine upon an energy spectrum of neutrons in boron neutron capture therapy. The method requires to measure the radioactivation of the foils. This study develops a simple modeling procedure of a high-purity Ge detector, which is used to measure the radioactivation, in order to calculate the detection efficiency with GEANT4. By changing four parameters from their manufacturing specifications of the detector, the simulated detection efficiency is able to reproduce the actual detection efficiency...
April 2, 2017: Applied Radiation and Isotopes
Hironobu Yanagie, Novriana Dewi, Syushi Higashi, Ichiro Ikushima, Koji Seguchi, Ryoji Mizumachi, Yuji Murata, Yasuyuki Morishita, Atsuko Shinohara, Shoji Mikado, Nakahiro Yasuda, Mitsuteru Fujihara, Yuriko Sakurai, Kikue Mouri, Masashi Yanagawa, Tomoya Iizuka, Minoru Suzuki, Yoshinori Sakurai, Shin-Ichiro Masunaga, Hiroki Tanaka, Takehisa Matsukawa, Kazuhito Yokoyama, Takashi Fujino, Koichi Ogura, Yasumasa Nonaka, Hirotaka Sugiyama, Tetsuya Kajiyama, Sho Yui, Ryohei Nishimura, Koji Ono, Sinichi Takamoto, Jun Nakajima, Minoru Ono, Masazumi Eriguchi, Kenichiro Hasumi, Hiroyuki Takahashi
OBJECTIVE: Boron neutron-capture therapy (BNCT) has been used to inhibit the growth of various types of cancers. In this study, we developed a (10)BSH-entrapped water-in-oil-in-water (WOW) emulsion, evaluated it as a selective boron carrier for the possible application of BNCT in hepatocellular carcinoma treatment. METHODS: We prepared the (10)BSH-entrapped WOW emulsion using double emulsification technique and then evaluated the delivery efficacy by performing biodistribution experiment on VX-2 rabbit hepatic tumour model with comparison to iodized poppy-seed oil mix conventional emulsion...
June 2017: British Journal of Radiology
Weirong Kang, Darren Svirskis, Vijayalekshmi Sarojini, Ailsa L McGregor, Joseph Bevitt, Zimei Wu
The efficacy of boron neutron capture therapy depends on the selective delivery of 10B to the target. Integrins αvβ3 are transmembrane receptors over-expressed in both glioblastoma cells and its neovasculature. In this study, a novel approach to dual-target glioblastoma vasculature and tumor cells was investigated. Liposomes (124 nm) were conjugated with a αvβ3 ligand, cyclic arginine-glycine-aspartic acid-tyrosine-cysteine peptide (c(RGDyC)-LP) (1% molar ratio) through thiol-maleimide coupling. Expression of αvβ3 in glioblastoma cells (U87) and human umbilical vein endothelial cells (HUVEC), representing tumor angiogenesis, was determined using Western Blotting with other cells as references...
May 30, 2017: Oncotarget
Yuko Kinashi, Natsuya Yokomizo, Sentaro Takahashi
AIM: To use the 53BP1 foci assay to detect DNA double-strand breaks induced by fractionated neutron beam irradiation of normal cells. MATERIALS AND METHODS: The Kyoto University Research Reactor heavy-water facility and gamma-ray irradiation system were used as experimental radiation sources. After fixation of Chinese Hamster Ovary cells with 3.6% formalin, immunofluorescence staining was performed. Number and size of foci were analyzed using ImageJ software. RESULTS: Fractionated neutron irradiation induced 25% fewer 53BP1 foci than single irradiation at the same dose...
April 2017: Anticancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"